We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

167 hedge funds and large institutions have $390M invested in Arbutus Biopharma in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

37% more call options, than puts

Call options by funds: $3.1M | Put options by funds: $2.26M

15% more capital invested

Capital invested by funds: $340M → $390M (+$49.8M)

9% more funds holding

Funds holding: 153 → 167 (+14)

3.45% more ownership

Funds ownership: 54.92% → 58.38% (+3.5%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

12% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 52

Holders
167
Holders Change
+14
Holders Change %
+9.15%
% of All Funds
2.24%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
25
Increased
46
Reduced
52
Closed
9
Calls
$3.1M
Puts
$2.26M
Net Calls
+$835K
Net Calls Change
+$778K

Top Buyers

Rank Fund Capital Flow
1
FC
Foursixthree Capital
New York
+$8.17M
2
WP
Woodline Partners
California
+$5.62M
3
Goldman Sachs
Goldman Sachs
New York
+$5.15M
4
Morgan Stanley
Morgan Stanley
New York
+$4.02M
5
TSC
Two Seas Capital
New York
+$2.42M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$2.21M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.19M
3
BlackRock
BlackRock
New York
-$570K
4
Squarepoint
Squarepoint
New York
-$536K
5
LP
LMR Partners
United Kingdom
-$517K
Name Holding Trade Value Shares
Change 		Change in
Stake
Aberdeen Group
26
Aberdeen Group
United Kingdom
$1.63M +$1.56M +467,383 New
QOP
27
Quinn Opportunity Partners
Virginia
$1.62M +$199K +59,634 +15%
Bank of America
28
Bank of America
North Carolina
$1.6M +$323K +96,922 +27%
FCH
29
Freestone Capital Holdings
Washington
$1.54M – – –
KCM
30
Kennedy Capital Management
Missouri
$1.46M -$4.58K -1,372 -0.3%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$1.4M +$958K +287,139 +249%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.22M -$15.3K -4,577 -1%
Millennium Management
33
Millennium Management
New York
$1.22M +$17.3K +5,192 +2%
N
34
Nuveen
North Carolina
$1.09M – – –
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$1.03M -$317K -94,996 -24%
Jane Street
36
Jane Street
New York
$980K +$936K +280,760 New
LWA
37
Ledgewood Wealth Advisors
New Hampshire
$972K – – –
ECM
38
Eisler Capital Management
United Kingdom
$968K +$917K +275,000 New
Swiss National Bank
39
Swiss National Bank
Switzerland
$964K – – –
Citigroup
40
Citigroup
New York
$914K +$247K +74,116 +39%
Barclays
41
Barclays
United Kingdom
$789K -$240K -72,088 -24%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$701K +$40.5K +12,159 +6%
UBS Group
43
UBS Group
Switzerland
$671K +$304K +91,287 +90%
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$640K -$216K -64,748 -26%
BFM
45
Boothbay Fund Management
New York
$566K – – –
Citadel Advisors
46
Citadel Advisors
Florida
$528K -$421K -126,145 -45%
Deutsche Bank
47
Deutsche Bank
Germany
$513K -$83K -24,903 -14%
Invesco
48
Invesco
Georgia
$487K +$232K +69,631 +100%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$463K – – –
AllianceBernstein
50
AllianceBernstein
Tennessee
$420K – – –
1
2
3 4 5

ABUS Hedge Fund Activity: Q1 2025 in Review

167 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2025, worth a combined $390M — up 15% from $340M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ABUS positions and 9 closed out — a net gain of 16 holders — while 46 added to existing stakes and 52 trimmed.

The largest buyer was Foursixthree Capital, opening a new position worth an estimated $8.17M. The largest seller was State Street, cutting an estimated $2.21M.

  • 167 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2025, up from 153 in Q4 2024.
  • Funds reported $390M of Arbutus Biopharma stock for Q1 2025, up 15% quarter-over-quarter.
  • 25 funds opened new Arbutus Biopharma positions in Q1 2025 and 9 closed out, a net change of +16 holders.
  • The largest Arbutus Biopharma buyer in Q1 2025 was Foursixthree Capital, an estimated $8.17M added.
  • The largest Arbutus Biopharma seller in Q1 2025 was State Street, an estimated $2.21M sold.

Based on aggregated 13F filings for Q1 2025.